MedTrace Logo

Biomarkers and Cardiac CT

NCT02381301 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 5000

Last updated 2017-03-28

No results posted yet for this study

Summary

Coronary artery disease (CAD) is the leading cause of morbidity and mortality in developed countries. In addition, many patients suffer from valvular and aortic disease. Although various tools are available to identify patients with cardiovascular (CV) disease at risk for major adverse cardiac events (MACE), the identification of these patients remains a clinical challenge.

One promising avenue is the use of different serum biomarkers involved in atherothrombosis which could provide an easy and cost-effective step in risk stratification.

Conditions

Interventions

BIOLOGICAL

Venous blood sampling prior to CCTA.

Sponsors & Collaborators

  • Maastricht University Medical Center

    lead OTHER

Principal Investigators

  • Harry J Crijns, MD, PhD · Maastricht University Medical Center

  • Bas Kietselaer, MD, PhD · Maastricht University Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2029-12-31
Completion
2029-12-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02381301 on ClinicalTrials.gov